Chronic Obstructive Pulmonary Disease

Respiratory·MeSH: Pulmonary Disease, Chronic Obstructive

Prevalence

6000.0 / 100K

Incidence

200.0 / 100K/yr

53 drugs in development·20 companies·31 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
ANORO ELLIPTA	Innoviva, Inc. (INVA)
breyna	Mylan II B.V. (MYL)
Ohtuvayre	Verona Pharma plc (VRNA)
RELVAR/BREO ELLIPTA	Innoviva, Inc. (INVA)
Trelegy	Royalty Pharma plc (RPRX)
Tyvaso (nebulized)	UNITED THERAPEUTICS Corp (UTHR)
Tyvaso DPI	UNITED THERAPEUTICS Corp (UTHR)
wixela inhub	Mylan II B.V. (MYL)
yupelri	Mylan II B.V. (MYL)
yupelri	Theravance Biopharma, Inc. (TBPH)

Phase 3(17)

Drug	Company
AZD6793	ASTRAZENECA PLC (AZN)
bgf	ASTRAZENECA PLC (AZN)
bgf mdi 320/14.4/9.6 μg	ASTRAZENECA PLC (AZN)
Ensifentrine (nebulized) - asthma	Verona Pharma plc (VRNA)
Ensifentrine (nebulized) - bronchiectasis	Verona Pharma plc (VRNA)
Ensifentrine (nebulized) - cystic fibrosis	Verona Pharma plc (VRNA)
Ensifentrine / glycopyrrolate fixed-dose combination	Verona Pharma plc (VRNA)
gff mdi 14.4/9.6 μg	ASTRAZENECA PLC (AZN)
itepekimab	Sanofi (SNY)
Itepekimab	Sanofi (SNY)
itepekimab sar440340	Sanofi (SNY)
lunsekimig	Sanofi (SNY)
Omalizumab	Cidara Therapeutics, Inc. (CDTX)
Tezepelumab	ASTRAZENECA PLC (AZN)
Tozorakimab	ASTRAZENECA PLC (AZN)
tozorakimab dose regimen 1	ASTRAZENECA PLC (AZN)
tozorakimab dose regimen 2	ASTRAZENECA PLC (AZN)

Phase 2(11)

Drug	Company
Ensifentrine 1.5 mg	Verona Pharma plc (VRNA)
Ensifentrine 3 mg	Verona Pharma plc (VRNA)
glyceryl bromide/formoterol inhalation aerosol	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
Glycopyrrolate	Verona Pharma plc (VRNA)
Glycopyrrolate 21.25 mcg	Verona Pharma plc (VRNA)
Glycopyrrolate 42.5 mcg	Verona Pharma plc (VRNA)
inopulse	Bellerophon Therapeutics, Inc. (BLPH)
tqc3927 inhalation aerosol	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
verekitug	Upstream Bio, Inc. (UPB)
Verekitug	Crinetics Pharmaceuticals, Inc. (CRNX)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(2)

Drug	Company
APG333	Apogee Therapeutics, Inc. (APGE)
pur1800	Pulmatrix, Inc. (PULM)

Preclinical(5)

Drug	Company
companion diagnostic tests for asthma	bioAffinity Technologies Inc. (BIAF)
ent-576	ENTEST GROUP, INC. (ETNI)
f528	GYRE THERAPEUTICS, INC. (GYRE)
labp-73	Landos Biopharma, Inc. (LABP)
zw1528	Zymeworks Inc. (ZYME)

Phase 4(8)

Drug	Company
BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL	ASTRAZENECA PLC (AZN)
budesonide/glycopyrronium/formoterol	ASTRAZENECA PLC (AZN)
dupilumab	Sanofi (SNY)
Dupilumab	Sanofi (SNY)
Nebulized Tyvaso	UNITED THERAPEUTICS Corp (UTHR)
treatment a	ASTRAZENECA PLC (AZN)
treatment b	ASTRAZENECA PLC (AZN)
treatment c	ASTRAZENECA PLC (AZN)

BioSniper tracks 53 drugs in development for Chronic Obstructive Pulmonary Disease across 20 companies.

There are 31 clinical trials targeting Chronic Obstructive Pulmonary Disease tracked by BioSniper.

The estimated prevalence of Chronic Obstructive Pulmonary Disease is approximately 6000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.